Absence of HBV and HCV, HTLV-I and -II, and human herpes virus-8 activation after allogeneic RBC transfusion in patients with advanced HIV-1 infection

Transfusion

Volumn 43, Issue 4, 2003, Pages 451-458

  Asmuth, David M ^a   Kalish, Leslie A ^b   Laycock, Megan E ^b   Murphy, Edward L ^b   Mohr, Beth A ^b   Lee, Tzong Hae ^b   Gallarda, James ^b   Giachetti, Cristina ^b   Dollard, Sheila C ^b   Van der Horst, Charles M ^b   Grant, Robert M ^b   Busch, Michael P ^b  

^a Division of Infectious Diseases   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; NUCLEIC ACID;

ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE TRANSMISSION; DOUBLE BLIND PROCEDURE; ERYTHROCYTE; ERYTHROCYTE TRANSFUSION; FEMALE; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HUMAN; HUMAN HERPESVIRUS 8; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN T CELL LEUKEMIA VIRUS 1; HUMAN T CELL LEUKEMIA VIRUS 2; IMMUNOSTIMULATION; LEUKOCYTE; MAJOR CLINICAL STUDY; MALE; RANDOMIZED CONTROLLED TRIAL; SEROPREVALENCE; TRANSFUSION; VIRUS ACTIVATION; VIRUS LOAD; VIRUS REPLICATION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANTIBODIES, VIRAL; DNA, VIRAL; DOUBLE-BLIND METHOD; ERYTHROCYTE TRANSFUSION; HEPACIVIRUS; HEPATITIS B VIRUS; HERPESVIRUS 8, HUMAN; HUMAN T-LYMPHOTROPIC VIRUS 1; HUMAN T-LYMPHOTROPIC VIRUS 2; HUMANS; PROSPECTIVE STUDIES; VIRAL LOAD; VIRUS ACTIVATION;

EID: 0037388735     PISSN: 00411132     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1537-2995.2003.00350.x     Document Type: Article

References (43)

1. Schnittman SM, Psallidopoulos MC, Lane HC, et al. The reservoir for HIV-1 in human peripheral blood is a T cell that maintains expression of CD4. Science 1989;245:305-8.
2. Zack JA, Arrigo SJ, Weitsman SR, et al. HIV-1 entry into quiescent primary lymphocytes: molecular analysis reveals a labile, latent viral structure. Cell 1990;61:213-22.
3. Lewis DE, Yoffe B, Bosworth CG, et al. Human immunodeficiency virus-induced pathology favored by cellular transmission and activation. FASEB J 1988;2:251-5.
4. Liu Z, Cumberland WG, Hultin LE, et al. CD8+ T-lymphocyte activation in HIV-1 disease reflects an aspect of pathogenesis distinct from viral burden and immunodeficiency. J Acquir Immune Defic Syndr Hum Retrovirol 1998;18:332-40.
5. Bednarik DP, Folks TM. Mechanisms of HIV-1 latency. AIDS 1992;6:3-16.
6. Sheppard HW, Ascher MS, McRae B, et al. The initial immune response to HIV and immune system activation determine the outcome of HIV disease. J Acquir Immune Defic Syndr 1991;4:704-12.
7. Liu Z, Cumberland WG, Hultin LE, et al. Elevated CD38 antigen expression on CD8+ T cells is a stronger marker for the risk of chronic HIV disease progression to AIDS and death in the Multicenter AIDS Cohort Study than CD4+ cell count, soluble immune activation markers, or combinations of HLA-DR and CD38 expression. J Acquir Immune Defic Syndr Hum Retrovirol 1997;16:83-92.
8. O'Brien WA, Grovit-Ferbas K, Namazi A, et al. Human immunodeficiency virus-type 1 replication can be increased in peripheral blood of seropositive patients after influenza vaccination. Blood 1995;86:1082-9.
9. Moss WJ, Ryon JJ, Monze M, et al. Suppression of human immunodeficiency virus replication during acute measles. J Infect Dis 2002;185:1035-42.
10. Busch MP, Lee TH, Heitman J. Allogeneic leukocytes but not therapeutic blood elements induce reactivation and dissemination of latent human immunodeficiency virus type 1 infection: implications for transfusion support of infected patients. Blood 1992;80:2128-35.
11. Vamvakas E, Kaplan HS. Early transfusion and length of survival in acquired immune deficiency syndrome: experience with a population receiving medical care at a public hospital. Transfusion 1993;33:111-8.
12. Busch MP, Collier A, Gernsheimer T, et al. The Viral Activation Transfusion Study (VATS): rationale, objectives, and design overview. Transfusion 1996;36:854-9.
13. Collier AC, Kalish LA, Busch MP, et al. Leukocyte-reduced red blood cell transfusions in patients with anemia and human immunodeficiency virus infection. The Viral Activation Transfusion Study: a randomized controlled trial. JAMA 2001;285:1592-601.
14. Dzik S, Aubuchon J, Jeffries L, et al. Leukocyte reduction of blood components: public policy and new technology. Transfus Med Rev 2000;14:34-52.
15. Busch MP, Laycock M, Mohr B, et al. Failure of serologic assays for diagnosis of hepatitis B and C virus infections in patients with advanced HIV. Abstract 235. In: 8th Conference on Retroviruses and Opportunistic Infections. Alexandria, VA: Foundation for Retrovirology and Human Health; 2001; Chicago, IL.
16. Spira TJ, Lam L, Dollard SC, et al. Comparison of serologic assays and PCR for diagnosis of human herpesvirus 8 infection. J Clin Microbiol 2000;38:2174-80.
17. Giachetti C, Linnen JM, Kolk DP, et al. Highly sensitive multiplex assay for detection of human immunodeficiency virus type 1 and hepatitis C virus RNA. J Clin Microbiol 2002;40:2408-19.
18. Lee TH, Stromberg RR, Heitman J, et al. Quantitation of residual white cells in filtered blood components by polymerase chain reaction amplification of HLA DQ-A DNA. Transfusion 1994;34:986-94.
19. Miley WJ, Suryanarayana K, Manns A, et al. Real-time polymerase chain reaction assay for cell-associated HTLV type I DNA viral load. AIDS Res Hum Retroviruses 2000; 16:665-75.
20. Chen IS, McLaughlin J, Gasson JC, et al. Molecular characterization of genome of a novel human T-cell leukaemia virus. Nature 1983;305:502-5.
21. Shimotohno K, Wachsman W, Takahashi Y, et al. Nucleotide sequence of the 3′ region of an infectious human T-cell leukemia virus type II genome. Proc Natl Acad Sci U S A 1984;81:6657-61.
22. Shimotohno K, Takahashi Y, Shimizu N, et al. Complete nucleotide sequence of an infectious clone of human T-cell leukemia virus type II: an open reading frame for the protease gene. Proc Natl Acad Sci U S A 1985;82:3101-5.
23. Shimotohno K, Golde DW, Miwa M, et al. Nucleotide sequence analysis of the long terminal repeat of human T-cell leukemia virus type II. Proc Natl Acad Sci U S A 1984; 81:1079-83.
24. Poles MA, Dieterich DT. HIV and hepatitis virus infection. Curr Infect Dis Rep 2000;2:177-84.
25. Lebovics E, Dworkin BM, Heier SK, et al. The hepatobiliary manifestations of human immunodeficiency virus infection. Am J Gastroenterol 1988;83:1-7.
26. Romet-Lemonne JL, McLane MF, Elfassi E, et al. Hepatitis B virus infection in cultured human lymphoblastoid cells. Science 1983;221:667-9.
27. Laskus T, Radkowski M, Wang LF, et al. Detection and sequence analysis of hepatitis B virus integration in peripheral blood mononuclear cells. J Virol 1999;73:1235-8.
28. Laskus T, Radkowski M, Piasek A, et al. Hepatitis C virus in lymphoid cells of patients coinfected with human immunodeficiency virus type 1: evidence of active replication in monocytes/macrophages and lymphocytes. J Infect Dis 2000;181:442-8.
29. Seto E, Yen TS, Peterlin BM, et al. Trans-activation of the human immunodeficiency virus long terminal repeat by the hepatitis B virus X protein. Proc Natl Acad Sci U S A 1988;85:8286-90.
30. Murphy EL, Watanabe K, Nass CC, et al. Evidence among blood donors for a 30-year-old epidemic of human T lymphotropic virus type II infection in the United States. J Infect Dis 1999;180:1777-83.
31. Murphy EL, DeVita D, Liu H, et al. Risk factors for skin and soft-tissue abscesses among injection drug users: a case-control study. Clin Infect Dis 2001;33:35-40.
32. Hershow RC, Galai N, Fukuda K, et al. An international collaborative study of the effects of coinfection with human T-lymphotropic virus type II on human immunodeficiency virus type 1 disease progression in injection drug users. J Infect Dis 1996;174:309-17.
33. Bartholomew C, Blattner W, Cleghorn F. Progression to AIDS in homosexual men co-infected with HIV and HTLV-I in Trinidad. Lancet 1987;2:1469.
34. Schechter M, Moulton LH, Harrison LH. HIV viral load and CD4+ lymphocyte counts in subjects coinfected with HTLV-I and HIV-1. J Acquir Immune Defic Syndr Hum Retrovirol 1997;15:308-11.
35. Kaplan JE, Khabbaz RF, Murphy EL, et al. Male-to-female transmission of human T-cell lymphotropic virus types I and II. Association with viral load. The Retrovirus Epidemiology Donor Study Group. J Acquir Immune Defic Syndr Hum Retrovirol 1996;12:193-201.
36. Wattel E, Vartanian JP, Pannetier C, et al. Clonal expansion of human T-cell leukemia virus type I-infected cells in asymptomatic and symptomatic carriers without malignancy. J Virol 1995;69:2863-8.
37. Chang Y, Cesarman E, Pessin MS, et al. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science 1994;266:1865-9.
38. Cannon M, Cesarman E. Kaposi's sarcoma-associated herpes virus and acquired immunodeficiency syndrome-related malignancy. Semin Oncol 2000;27:409-19.
39. Gao SJ, Kingsley L, Hoover DR, et al. Seroconversion to antibodies against Kaposi's sarcoma-associated herpes-virus-related latent nuclear antigens before the development of Kaposi's sarcoma. N Engl J Med 1996;335:233-41.
40. Min J, Katzenstein DA. Detection of Kaposi's sarcoma-associated herpesvirus in peripheral blood cells in human immunodeficiency virus infection: association with Kaposi's sarcoma, CD4 cell count, and HIV RNA levels. AIDS Res Hum Retroviruses 1999;15:51-5.
41. Osman M, Kubo T, Gill J, et al. Identification of human herpesvirus 8-specific cytotoxic T-cell responses. J Virol 1999;73:6136-40.
42. Wang QJ, Jenkins FJ, Jacobson LP, et al. CD8+ cytotoxic T lymphocyte responses to lytic proteins of human herpes virus 8 in human immunodeficiency virus type 1-infected and -uninfected individuals. J Infect Dis 2000;182:928-32.
43. Hudnall SD, Rady PL, Tyring SK, et al. Hydrocortisone activation of human herpesvirus 8 viral DNA replication and gene expression in vitro. Transplantation 1999;67:648-52.